Anaplastic Large Cell Lymphoma Recruiting Phase 2 Trials for Nivolumab (DB09035)

Also known as: Lymphomas, Anaplastic Large-Cell / Anaplastic large-cell lymphoma / Large cell (Ki-1+) lymphoma / Lymphoma, Large-Cell, Anaplastic / Anaplastic large cell lymphoma, CD30-positive

IndicationStatusPhase
DBCOND0028602 (Anaplastic Large Cell Lymphoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01703949Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaTreatment